MedTrace Logo

Study in Healthy Adults Evaluating PF-07202954

NCT04857437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-09-20

Study results available
· View outcomes & findings →

Summary

The study is planned as a 3 part design with investigator and participant blinded (sponsor-open), placebo controlled, randomized, dose escalation in Part 1 and Part 2; and a randomized, open label design, in Part 3 (if conducted).

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Liver Fibrosis

Interventions

DRUG

PF-07202954 Repeat Dose

10, 30, 100, 300, 600, 1200 milligrams (mg)

DRUG

PF-07202954 Single Dose

10, 30, 100, 300, 600, 900, 1200 milligrams (mg)

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-13
Primary Completion
2021-09-17
Completion
2021-09-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04857437 on ClinicalTrials.gov